We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

68 hedge funds and large institutions have $398M invested in KalVista Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

52% more capital invested

Capital invested by funds: $261M → $398M (+$137M)

25% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 16

19% more funds holding

Funds holding: 57 → 68 (+11)

3.33% more ownership

Funds ownership: 77.28% → 80.61% (+3.3%)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

Holders
68
Holders Change
+11
Holders Change %
+19.3%
% of All Funds
1.47%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
17
Increased
20
Reduced
16
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PC
Polar Capital
United Kingdom
+$23.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$15.9M
3
Millennium Management
Millennium Management
New York
+$2.09M
4
O
OrbiMed
New York
+$1.96M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.41M

Top Sellers

Rank Fund Capital Flow
1
SHI
SV Health Investors
Massachusetts
-$15.5M
2
VMI
VHCP Management III
New York
-$6.81M
3
BI
BVF Inc
California
-$4.99M
4
VMI
VHCP Management II
New York
-$4.03M
5
BC
Broadfin Capital
New York
-$2.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
SHI
1
SV Health Investors
Massachusetts
$52.4M -$15.5M -716,654 -28%
RCM
2
RA Capital Management
Massachusetts
$41.2M – – –
VC
3
Vivo Capital
California
$38.9M – – –
PC
4
Polar Capital
United Kingdom
$32.9M +$23.2M +1,070,300 +1,357%
VMI
5
VHCP Management III
New York
$27.8M -$6.81M -314,301 -24%
EAM
6
Eventide Asset Management
Massachusetts
$25.8M – – –
Fidelity Investments
7
Fidelity Investments
Massachusetts
$21M +$15.9M +735,014 New
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$19M +$1.41M +65,000 +11%
DM
9
Deerfield Management
New York
$18.6M – – –
VMI
10
VHCP Management II
New York
$16.4M -$4.03M -185,699 -24%
GTC
11
Ghost Tree Capital
New York
$11.4M -$542K -25,000 -6%
IVM
12
InterWest Venture Management
California
$11.1M – – –
Vanguard Group
13
Vanguard Group
Pennsylvania
$10.2M +$359K +16,547 +5%
Invesco
14
Invesco
Georgia
$8.98M +$808K +37,268 +13%
IBT
15
International Biotechnology Trust
United Kingdom
$6.06M -$2.31M -106,383 -33%
ACP
16
Acuta Capital Partners
California
$5.88M +$705K +32,500 +19%
BC
17
Boxer Capital
California
$5.72M – – –
Renaissance Technologies
18
Renaissance Technologies
New York
$4.58M -$418K -19,300 -11%
SB
19
Samsara BioCapital
California
$3.39M -$683K -31,500 -21%
Millennium Management
20
Millennium Management
New York
$2.76M +$2.09M +96,470 New
O
21
OrbiMed
New York
$2.59M +$1.96M +90,500 New
Geode Capital Management
22
Geode Capital Management
Massachusetts
$2.38M -$17K -786 -0.9%
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$2.08M +$1.33M +61,414 +552%
FI
24
Fosun International
China
$2.03M -$1.41M -64,837 -47%
BlackRock
25
BlackRock
New York
$2.01M +$546K +25,179 +56%
1
2 3

KALV Hedge Fund Activity: Q1 2019 in Review

68 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2019, worth a combined $398M — up 52% from $261M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new KALV positions and 6 closed out — a net gain of 11 holders — while 20 added to existing stakes and 16 trimmed.

The largest buyer was Polar Capital, adding an estimated $23.2M. The largest seller was SV Health Investors, cutting an estimated $15.5M.

  • 68 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2019, up from 57 in Q4 2018.
  • Funds reported $398M of KalVista Pharmaceuticals stock for Q1 2019, up 52% quarter-over-quarter.
  • 17 funds opened new KalVista Pharmaceuticals positions in Q1 2019 and 6 closed out, a net change of +11 holders.
  • The largest KalVista Pharmaceuticals buyer in Q1 2019 was Polar Capital, an estimated $23.2M added.
  • The largest KalVista Pharmaceuticals seller in Q1 2019 was SV Health Investors, an estimated $15.5M sold.

Based on aggregated 13F filings for Q1 2019.